Australia · Delayed Price · Currency is AUD Cynata Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Phase II GVHD and phase III OA trials failed to meet efficacy endpoints, with high placebo responses and no significant safety concerns. The kidney transplant trial continues, while other programs are under review as the board evaluates strategic options.
-
Two pivotal clinical trial readouts in osteoarthritis and GvHD are expected in Q2 2025, with both having the potential to transform commercial prospects. Cash runway extends beyond these milestones, and partnership discussions are ongoing, pending trial outcomes.
-
Major clinical trial readouts in osteoarthritis and GVHD are expected in Q2 next year, with strong cash reserves and a unique manufacturing platform positioning the company for potential commercialization and partnerships. Ongoing trials and strategic initiatives target large unmet-need markets.
Fiscal Year 2025
-
Clinical pipeline advanced with key trials nearing completion and major readouts expected within a year. Cash runway extends to mid-2026, covering all milestones, and regulatory feedback supports a clear path to approval in Australia for osteoarthritis.
-
Cash reserves of AUD 8.5M support operations through H2 2026, with major clinical readouts for GvHD and osteoarthritis expected within a year. Strong clinical progress, promising DFU results, and sector validation from Mesoblast's FDA approval are driving partner interest.
-
Strong cash position and clinical progress marked the quarter, with positive DFU phase I results, advancing GVHD and osteoarthritis trials, and new research validating iPSC-derived MSC advantages. Focus remains on GVHD, manufacturing scale-up, and strategic partnering.
Fiscal Year 2024
-
Recent clinical trial in diabetic foot ulcers showed strong safety and efficacy, with the active MSC dressing group achieving substantial wound reduction compared to standard care. Capital raising has strengthened the cash position, supporting ongoing trials and commercial activities.